Mittal joins the firm following a thirteen-year career at Biocon Limited, where he most recently served as Managing Director and CEO. During his time at Biocon, he steered the company’s strategic expansion, oversaw the commercialization of the GLP-1 portfolio, and navigated complex regulatory landscapes in international markets. His appointment comes as Syngene looks to capitalize on its existing scientific infrastructure, which spans over 3 million square feet of facilities across India and the U.S. and employs more than 5,700 scientists.

Executive Chairperson Kiran Mazumdar-Shaw cited Mittal’s track record in business transformation as a primary driver for the hire. For his part, Mittal identified his immediate priorities as enhancing commercial execution and strengthening delivery discipline. With a workforce exceeding 8,300 people, the company remains a critical partner for major pharmaceutical firms including BMS, GSK, Zoetis, and Merck KGaA. Mittal aims to leverage these existing client relationships to drive the next phase of growth while maintaining the company's focus on cost competitiveness and scientific output.